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ABSTRACT 
 
OBJECTIVES: This is a prospective analytical study to find  the incidence of gestational 
diabetes in 100 HIV positive antenatal  women on anti retroviral therapy and to find the 
association between the antiretroviral regimen used and the occurrence of Gestational diabetes  
mellitus (GDM). 
 
METHODS: The DIPSI criteria was used to diagnose a patient with GDM. This is a one step 
glucose challenge test where the patient is given 75g of oral glucose irrespective of fasting state 
and a 2 hour glucose value greater than or equal to 140mg/dl  is diagnostic of GDM. 
 
RESULT: 100 antenatal patients on antiretroviral therapy were taken in this study.The overall 
incidence of GDM came to 11% in my study. The maternal risk factors that could have caused 
GDM were as follows.   Out of 54 primigravida only 2 had GDM (i.e.) 3.7%, second gravida 
were a  total of 39 patients of which 5 women (12.8%) had GDM, and 3rd gravid out of 6 patients 
2 had GDM (33.3%). We had one 4th gravid and she had GDM (100%).As the number of living 
children increase, the risk of GDM increases, in primigravida the risk was 4.6% and in 
mulligravida it was 68.2%. In my study I had 3 patients with history of  IUD /still birth of which 
2 women had GDM (66.7%)Of 4 patients with a history of previous GDM, 3 patients 75% had 
recurrent GDM. Of 4 patients with BMI >30, 2 patients had GDM (50%) 
 
17 Patients had 1st degree relative with diabetes of which 6 patients (35.3%) had GDM.  A 
history of big baby (Bwt >4kg) is a proven risk factor for GDM. In my study, 3 patients had 
history of previous baby birth weight >4kg of which 2 patients had GDM in this pregnancy. The 
risk is 66.7% . The 100 patients in my study, fall into 3 different antiretroviral regimens. 
 
Tenofovir, Lamivudine, Lopinavir – 1 patient ,Tenofovir, Lamivudine ,Efavirenz - Had majority 
patients, 81 patients of which 9 had GDM (11.1%) Zidovidine, lamivudine, Nevrapine 18 
patients of which 1 patient (5.6%) had GDM.There was no significant association between GDM 
( P value 0.782)and the regimens used in my study.96 patients had live birth of which 7 patients 
(7.3%risk) had GDM..2 patients had IUD of which 1 patient (50% risk) had GDM and 2 patients 
had still birth of which both the patient  (100%) had GDM.The mean age of patients with GDM 
is 29.10 yrs (S.D. + 3.3)and the mean BMI is 27.85 (SD + 3.633)The mean weight gain in 
patients with GDM is  9.8kg  and the mean CD4 count for patients with GDM is 699.40.The 
univarite analysis shows statistical significance between GDM and parity, previous history of 
GDM, previous birth weight >4 kg, BMI >30, previous IUD / Still births and a 1st degree relative 
with GDM.Multivariate analysis (logistic regression) was used and it was found that previous 
IUD/still birth (OR=89.299), present pregnancy weight gain (OR=3.588) and 1st degree relative 
with diabetes (OR=18.298) were significant associated with variables in predicting the 
occurrence of GDM. 
 
CONCLUSION 
There  is no significant increase in the overall incidence of GDM in HIV patients. Statistically, 
there is no significant association between the antiretroviral drugs used in my study and the 
GDM incidence (p>0.05).By logistic regression, my study has proven that a history of 1st degree 
relative with diabetes, previous IUD/still birth and weight gain in this pregnancy are significant 
variables contributing to GDM in the 11 patients in my study. 
 
Keywords: HIV, Gestational diabetes  mellitus , anti retroviral therapy, protease inhibitors, 
newer regimen. 
1 
 
 
 
INTRODUCTION 
 
 Transmission of HIV during antenatal period from mother to baby is the 
key mode in which children acquire HIV. Annually about 14,000 new HIV 
infections occur in India among children. About 10,000 deaths from HIV 
infection occur among children in India. United Nations General Assembly 
adopted a policy towards elimination of pediatric HIV by 2015.India has 
adopted the same policy. Anti retroviral treatment is the way to this achieve 
this goal. 
 
 Earlier Nevirapine and protease based inhibitors had been used . 
 
 The PI-based regimen can reduce the risk of drug resistance and side 
effects from Nevirapine. The PI-based regimens have been highly successful in 
controlling HIV viral load and can reduce vertical viral transmission but their 
benefits are compromised by numerous undesirable side effects.  
 
 These include tissue insulin resistance and overt hyperlipidemia, which 
may be aggravated by the normal physiologic changes of carbohydrate and 
lipid metabolism during pregnancy. Impaired fetal growth also has been 
concerned because higher incidence of low birth weight was reported.  
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Based on the new NACO guidelines december 2013 
 Pregnant women newly diagnosed with HIV are started on Tenofovir, 
Lamivudine, Efavirenz irrespective of CD4 count or clinical stage. 
 If a patient is already on a particular ART regimen the same is 
continued. 
 If a patient is already exposed to NNRTI (Nevirapine),the risk of 
resistance to efavirenz based therapy is high. So in such patients 
protease inhibitor based regimen is started – Tenofovir, Lamivudine, 
Ritonavir / Lopinavir. 
 
  
Aim of the study 
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AIM OF THE STUDY 
 
 To study the incidence of Gestational diabetes mellitus in antenatal 
mothers diagnosed with HIV and who are on Anti retroviral therapy. 
            To study the association between Anti Retroviral regimens and 
occurrence of Gestational Diabetes Mellitus  
  
Materials and Methods 
  
4 
 
 
 
MATERIALS AND METHODS: 
 
STUDY DESIGN 
          PROSPECTIVE ANALYTICAL STUDY 
 
SETTING: 
 INSTITUTE OF OBSTETRICS AND GYNECOLOGY 
 EGMORE, CHENNAI-8. 
 
SAMPLE : 
 100 HIV positive pregnant women on Anti retroviral therapy for a   
period from september 2014 to august 2015 
 
MATERIALS AND METHODS: 
 100 pregnant women infected with HIV and on  Antiretroviral therapy 
for prevention of vertical transmission of HIV at Institute of Obstetrics and 
Gynaecology, Egmore from September 2014 to August 2015.  
 
 The women who had pregestational diabetes or received corticosteroids 
during pregnancy were excluded from the study. One hundred cases met the 
criteria. They were closely monitored during pregnancy. The information 
recorded including HIV history, obstetric data, GDM risk factors (previous 
GDM, BMI ≥ 30 kg/m2, 1st degree relative with DM, history of stillbirth , 
previous birth weight > 4,000 gm, body mass index (BMI), total weight gain 
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and adverse drug effect from prior to current regimens. In addition to routine 
prenatal blood test, fasting blood sugar, CD4 count, viral load was done.  
 
 Screening for GDM with the DIPSI criteria had been done on all HIV-
positive pregnant women at 16 weeks, 24-28 weeks and 32 weeks.  The 
patients were given 75-g oral glucose irrespective of fasting state and a cut off 
of  ≥ 140 mg/dL was diagnostic of GDM. 
 The patients were followed upto 6 weeks after delivery and various details 
collected. 
         
INCLUSION CRITERIA: 
 Patients not on corticosteroids 
 Patients not a known case of type 2 DM 
 Willing for follow up 
 
EXCLUSION CRITERIA: 
 Patients on corticosteroids 
 Patients who are Pregestational diabetics 
 Not wiiling for follow up 
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EXPECTED OUTCOME OF THE STUDY: 
 Protease inhibitor  based antiretroviral therapy is known to cause 
glucose intolerance in patients  
 To come up with incidence of GDM in patients on antiretroviral therapy  
at IOG and to study their association with GDM. 
  
Review of Literature 
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REVIEW OF LITERATURE 
 
 The emergence and pandemic of acquired immunodeficiency syndrome 
has posed a great challenge to public health in recent times. After sudden 
appearance of syphilis in Europe five hundred years ago,Rarely has any disease 
had such great impact on  medicine, science and society and caused so much 
panic among public and government  all over the world as AIDS. The full 
impact of the disease is not  known for many years because of silent spread and 
evolution of this disease. 
 
 The first report of this disease came in  1981  from two cities, Los 
Angeles and New York  .There was a unexplained sudden occurrence in large 
numbers of two uncommon illness in homosexual young adults and drug 
addicts, namely Kaposi‘s sarcoma and pneumocyctis carinii pneumonia. These 
patients had  no immunity left in their body and hence became susceptible to  
many life threatening  infections and malignancies by relatively  avirulent 
organisms . The above condition was called as Acquired Immunodeficiency 
syndrome(AIDS) 
 
 
 In 1985 serological test  namely ELISA was discovered for detection of 
antibodies against HIV . This helped further in an accurate estimation of the 
extent of the infection. Till then , the infection could be diagnosed only when 
patients developed the characteristic clinical features such as opportunistic 
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infections or malignancies. These end stage cases represented only tip of the 
iceberg. Serological testing of high risk groups, blood donors and others 
revealed a very large  reservoir of HIV in patients and carriers all over  the 
world.  The rate of infection has been steadily mounting over the years. The 
saddest part is that the developing world has to carry the brunt of this disease.   
 
HIV VIRUS 
 HIV causing AIDS belongs to the subgroup lentivirus  of  Retroviridiae 
family   
 
Structure: 
 HIV is a spherical enveloped virus 90-120mm in size  The nucleocapsid 
is made of 
- an outer shell  which is icosahedral 
- an inner  core  which is cone shaped . It encloses the ribonucleoproteins.  
 
 The genome  has two positive sense RNA copies which are single 
stranded and identical, hence diploid .The reverse transcriptase enzyme which 
is the characteristic feature of this virus is present along with the viral RNA. 
 
 Once the virus  infects a host cell  the viral RNA is first transcribed by 
the enzyme  into single stranded DNA  and it  is then transcribed  into a double 
stranded DNA This then  integrates into the  host cell chromosome to form the 
provirus which has the capability to stay latent for a long time in the host cell 
During that period it continuously affects the  host cell function In response to 
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stimulation by viral promoters the pro virus begins  viral replication by 
initiating  the synthesis  various components including viral RNA  During  viral 
replication  naked virus buds out of  the host cell surface membrane During  
this process it acquires a lipoprotein envelope, of which lipid is derived from 
surface membrane of host cell and the glycoprotiens  are virus coded The virus 
coded envelope proteins include surface projecting knob like spikes  and 
transmembrane anchoring  pedicles The  surface spikes  bind to the CD4+ 
receptors on the susceptible host cell  Transmembrane pedicles cause cell 
fusion. 
 
VIRAL GENES AND ANTIGENS: 
 The genome of HIV has three structural genes (gag,pol,env) 
characteristic of  all retroviruses . It also has other regulatory and non structural  
genes which are specific for the virus . The products of the genes both the 
structural and non structural act as antigens. The sera of infected persons 
contain antibodies to them. Detection of these antigens and antibodies is useful 
in the diagnosis and prognosis of HIV infection. 
 
GENES CODING FOR STRUCTURAL PROTIEN: 
1. The gag gene codes for  viral shell and  core . It is present as p53 a 
precursor protein . This p53  is cleaved into  p15, p18 and p24 which 
make up  viral core and shell. The major core antigen p24 can be 
detected in serum even before antibodies can appear. Later in  course of 
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infection there is decline of p24 antibodies . The re-appearance of p24 
antigen in circulation denotes exacerbation of the illness. 
2. The env gene codes for the synthesis of  envelope glycoprotein 
gp160,which is then cleaved into  gp 120 which contributes to the 
surface spikes and gp 41 that forms  a transmembrane anchoring protein  
The glycoprotein  gp 120 is the major envelope antigen. Antibodies to 
gp 120 antigen are seen in circulation till the end stage of the disaese. 
3. The pol gene codes for the polymerase reverse transcriptase It also codes 
for other enzymes like endonuclease and protease. It is present as 
precursor protein which is then divided into proteins p31,p51 and p66. 
 
NON STRUCTURAL PROTEINS: 
 Tat (trans activating gene) enhancing expression of all viral genes. 
 Nef (negative factor gene) down regulating viral replication. 
 Rev ( regulator of virus gene) enhancing expression of structural 
proteins. 
 Vif (  viral infectivity factor gene)influencing infectivity viral particles. 
 Vpu (is present in HIV1 ) and  vpx (present in HIV2) enhances 
maturation and  release of  the progeny viruses from the  cells  
 Vpr stimulating the promoter region of the virus 
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 LTR ( LONG TERMINAL REPEAT)  containing sequences giving 
promoter enhancer and integration signals. 
 
 
 HIV 1 strains have been classified into atleast 10 subtypes . These 
subtypes are grouped under A to J and form  Group M(major)  these cause   
majority of HIV1 infections all over the world. Subtype A is most common 
worldwide. Subtype B is most common in America and Europe . The most 
common subtypes in  Africa are A,C and D while in Asia most common 
subtypes are E ,C and B. Subtype E is prevalent in Thailand. In India and China 
subtype C is the most common. 
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PATHOGENESIS: 
  HIV virus causes infection by entering through blood or  tissues of a 
person it then comes in contact with a susceptible host cell which is mainly the 
CD4 lymphocyte . 
 
 CD4 Lymphocyte is the recptor for the virus and hence the virus infects 
any cell that bears CD 4 antigen on its surface  
 
 Envelope glycoprotein gp120 causes Specific binding of the virus to the 
CD4 receptor of the host cell . However cell fusion is necessary for infection to 
take place. This is  by gp41 transmembrane protein.Co receptor molecules, 
CXCR4 for T  cell tropic virus and CCR5 for  macrophage tropic virus are also 
necessary for cell fusion and virus entry  
 
 After   viral fusion with the host cell the HIV genome is uncoated and 
internalized into the cell The reverse transcriptase enzyme transcribes viral 
RNA into double stranded  DNA. This ds DNA with the help of the enzyme 
integrase is integrated  into the genome of the infected host  cell , thus resulting 
in latent infection in the meanwhile, there is lytic infection from time to time 
which releases the progeny virions  that infect other cells. In an affected 
individual HIV can be detected from lymphocytes ,  breastmilk , blood, 
cervical secretions ,tears, saliva, semen  urine and cell free plasma  
 
 The main pathogenesis in HIV infection is the virus destroying the CD4 
lymphocytes  The T4 cells decrease and  T4:T8 cell ratio is reversed. Viral 
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infection can suppress the function of infected cells without causing structural 
damage. Infected T4 cells do not produce normal amount of gamma interferon, 
IL-2 and other lymphokines. This markedly decreases the cell mediated 
immunity. 
 
 Though  cellular mediated immune response is largely affected  humoral 
mechanism also seems to be influencd to an extent. Helper T cell activity is 
needed for optimal B cell function, especially in responding to thymus 
dependent antigen.  Hence  patients  having AIDS are not able to respond to 
new antigens. 
 
 An important feature of AIDS is polyclonal B cell activation resulting in 
hypergammaglobulinemia . All classes of immunoglobulins are involved but 
levels of IgG and IgA are raised. In infants and children additionally IgM levels 
are also elevated.  The hypergammaglobulinemia is more of a hindrance than a 
help because they are  mostly  useless immunolglobulins to irrelevant antigens 
and autoantibodies. This may also be responsible for Type 3 hypersensitivity 
allergic reactions due to immune complexes. 
 
 Monocyte - macrophage function is also affected mainly  due to 
decreased secretion of  activating factors by the T lymphocytes  resulting in 
decreased chemotaxis ,antigen presentation and intracellular killing by  
monocytes macrophages . The activity of natural killer cells and cytotoxic T 
lymphocytes are also affected. The principal immunological abnormalities seen 
in HIV are: 
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Features that characterize AIDS are: 
 Lymphopenia 
 Selective T cell deficiency- reduction in number of CD4 cells ,inversion 
of T4:T8 ratio 
 Decreased delayed hypersensitivity 
 Hypergammaglobulinemia -   especially IgG and IgA  and IgM in 
children. 
 Polyclonal  activation of B cells and increased spontaneous secretion of 
Ig 
 
Other consistently observed features: 
 Decreased in vitro lymphocyte proliferative response  to mitogens and 
antigens. 
 Decreased cytotoxic response by T cells and NK cells 
 Decreased antibody response to new antigens 
 Altered monocyte macrophage function 
 Elevated levels of immune complexes in serum.  
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HIV IN PREGNANCY 
 
INCIDENCE:   
 According to WHO 35.3 million people were living with HIV in 2012 
which is an increase from the previous years  as more people are receiving 
antiretroviral therapy There were 2.3 million new HIV infections globally 
which is a 33% decline from 2001 In USA the number of new cases of HIV has 
decreased significantly. Advancement and availability of treatment has 
decreased the rate of mother to child transmission of the disease, has given  
control over the progression of the disease and the development of 
opportunistic infections and full blown AIDS. In contrast in the third world the 
number of deaths and vertical transmission has increased. The advances in 
therapy have no effect in the poorer countries due to lack of accessibility of 
these drugs. Worldwide 25-30% of HIV infected patients are women of which  
90% of them are in the age group of 20-49 years.  
 
MATERNAL INFECTION: 
 Maternal HIV infection is acquired mainly by sexual contact or by 
transfusion. The exact  incidence of HIV in pregnancy is unknown. But the fact 
remains that the incidence is on the rise in developing and developed countries. 
In most Asian countries the infection rate is less than 0.5% . Studies have 
demonstrated that pregnancy does not affect the progression or the survival of 
HIV infected women.  Whereas  there are debates regarding the effect of HIV 
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infection on pregnancy outcome.  The main association of HIV are preterm 
birth and fetal growth restriction. However there can be multiple confounding 
factors like alcohol use, drug abuse ,advanced maternal disease and 
malnutrition. 
 
IMPLICATION  FOR FETAL INFECTION: 
 Almost 15-25% of babies born to HIV positive mothers show presence 
of the disease by 1 year of age. The virus is secreted in  breast milk  and hence 
breast feeding is contraindicated in HIV. In non breast feeding mothers 60-70% 
of transmission occurs during delivery while the rest occurs  antepartum. 
 
 The factors which lead to fetal infection can be classified into maternal 
and fetal factors. 
 
 Maternal factors include severity of disease assessed by CD4+ count or 
by measuring viral RNA copies. The presence of maternal antibodies against 
certain epitopes or against the principal neutralizing domain of the envelope 
protein gp120 is predictive of the absence of infection in the newborn. The 
number of RNA copies correlates with the risk of vertical transmission. In 
infected women  if the viral load is less than 1000 copies /ml risk of 
transmission is 0-10%, 17% with viral load of 1000-10,000 copies,33% if load 
more than 10,000 copies. 
 
 The guidelines to start anti retroviral therapy in pregnant women is CD4 
count <400/mm3 or a viral load of >1000 copies/ml  by PCR assay. This viral 
17 
 
 
load is the threshold recommended by ACOG for the performance of cesarean 
delivery. A CD4 count <200/mm3  is an indication for prophylactic treatment 
for opportunistic infections. 
 
 With respect to obstetrical factors, the frequency of vertical transmission 
increases with the duration of ruptured membranes and cesarean delivery has a 
protective effect. The frequency of vertical transmission decreases if the 
mother is on HAART (Highly Active Anti Retroviral Therapy) lowers the risk 
of vertical transmission to the baby  irrespective of the maternal viral  load, 1% 
in cases of <1000 RNA copies/ml,6% with levels  1000-10,000 RNA copies/ml 
and 13% if RNA copies >10,000 copies/ml. 
 
 Most of the infants born to HIV positive mothers exhibit no signs of 
infection. A few of them may have features of HIV embryopathy , 
characterized by growth retardation, craniofacial abnormalities and 
microcephaly. Most of the infants born to HIV positive mothers are 
seropositive when born due to passive transfer of maternal antibodies. But 
these antibodies gradually decline and disappear by 6 months of age. 
 
 United Nations General Assembly adopted a resolution to work towards 
elimination of pediatric HIV by 2015.Government of India is committed to this 
goal 
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MANAGEMENT: 
 The  most important issues in the management of HIV is the detection. 
CDC recommends screening for HIV for antenatal mothers in their first visit. 
Thereafter their management involves a multidisciplinary approach involving 
social workers, obstetrician , paediatrician,nutrtionalists and many other health 
care providers. If an HIV infected mother decides to continue her pregnancy 
she needs to have regular CD4 counts and ultrasound to monitor the growth of 
the fetus. 
 
DRUGS USED ANTIRETROVIRAL THERAPY: 
NUCLEOSIDE AND NUCLEOTIDE REVERSE TRANSCRIPTASE 
INHIBITORS: 
 Zidovudine, Lamivudine, Stavudine, , Abacavir, Emtricitabine, 
Didanoside Tenofovir (NtRTI). 
 
NON NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITORS: 
  Efavirenz ,Nevirapine 
 
INTEGRASE INHIBITOR: 
 Raltegravir 
FUSION INHIBITOR: 
 Enfuviritide 
PROTEASE INHIBITOR: 
 Ritonavir, Lopinavir, Atazanavir, Nelfinavir, Saquinavir, Indinavir,  
Amrepinavir, Fosamprenavir , Tipranavir , Darunavir 
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ENTRY INHIBITORS(CCR5/CXCR4 antagonists)  
Maroviroc. 
*The drugs which are highlighted are available in the  NACO ART 
programme.  
 
NRTI: 
 Zidovudine (AZT, ZDV) 
 Effective against HIV-1 & 2 
 Available as tablet and syrup 
 Reduces the rate of vertical transmission 
 Adult Dose: 300mg twice daily 
 Available as Fixed Dose Combination in the National ART programme  
 Preferred over Tenofovir in first line ART in  HIV patients  having 
Haemoglobin >9G% 
 
Stavudine(D4t) 
 Effective against HIV-1 & 2 
 High oral bioavailability 
 Available as tablet (for adults and children) 
 Adult Dose: 30mg twice daily 
 Stavudine has been phased out of first line ART regimens in children 
and adults  
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 Stavudine administration is reserved for the alternate / second line 
regimens [in the inevitable situations with the approval of State AIDS 
Clinical Expert Panel (SACEP)] 
Lamivudine (3TC) 
 Effective against HIV-1 & 2 and HBV 
 Excellent drug, well tolerated and least toxic 
 Synergistic action with Zidovudine & Stavudine  
 Low genetic barrier for resistance 
 Lamivudine resistant mutants reduce viral fitness 
 Adult Dose: 150mg twice daily 
 Available as Fixed Dose Combination in the  National ART programme  
 
TOXICITIES OF NRTIs 
DRUGS ZIDOVUDINE STAVUDINE LAMIVUDINE 
SHORT 
TERM 
Headache ,nausea 
vomiting, malaise 
diarrhea, bone marrow 
suppression, 
anemia(macrocytic) 
 Skin rash (very rash) 
MEDIUM 
TERM 
bone marrow 
suppression, anemia, 
hyperpigmentation, 
lactic acidosis 
lactic acidosis, 
peripheral 
neuritis, 
pancreatitis 
 
LONG 
TERM  
Lipodystrophy, 
dyslipedemia  
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ABACAVIR( ABC): 
 Abacavir is available along with Lamivudine (3TC) in formulations of 
60/30 mg and 300/150 mg 
 Can be taken with meal 
 Common side-effects are nausea vomiting Malaise Headache & 
Diarrhoea  
 No dose adjustment in renal failure  
 but the  combined formulations (with 3TC) are NOT to be used in 
patients with creatinine clearance less than 50 ml/min. 
 Major complication: Hypersensitivity reaction 
 Abacavir hypersensitivity is linked to  HLA-B 5701 gene 
 <5% of adults and children  
 Usually during first 6 weeks of therapy, but may occur at any time! 
 Rash, fever, fatigue, diarrhoea, vomiting, abdominal pain, arthralgia, 
respiratory symptoms, increased liver enzymes, lymphadenopathy,                     
mucus membrane ulcerations 
 Potentially fatal 
 STOP Abacavir and NEVER restart  
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NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITOR(NtRTI) 
TENOFOVIR: 
 Mechanism and site of action similar as NRTIs   (Already in mono 
phosphate form, need only diphosphorylation whereas other NsRTIs 
need triple phosphorylation)  
 Potent drug against HIV-1 & 2 and HBV 
 Usually well tolerated; Flatulence may bother some 
 Nephrotoxicity: low incidence; Fanconi syndrome (hypophosphataemia, 
hyperuricemia, proteinuria, normoglycaemic glycosuria) and rarely 
Acute Renal Failure 
 Can reduce bone mineral density  
 Adult dose: 300 mg tablet once daily 
 
NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS 
(NNRTIS) 
 Non-competitively block Reverse Transcriptase at the active site at a 
distinct point from NRTIs  
 Active against HIV-1 replication cycles as NRTIs 
 Not active against HIV-2 replication cycles  
 Inducers of the hepatic cytochrome P450 enzyme system (CYP3A4 and 
others) – leading to many drug interactions  
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 Primarily excreted via hepatic route 
 NNRTIs in Programme: Nevirapine and Efavirenz  
 
NEVIRAPINE: 
 Active against HIV-1; Not active against HIV-2 
 Excellent oral bioavailability, not food dependent 
 Nevirapine is a substrate and potent inducer of the hepatic cytochrome 
P450 enzyme system (CYP3A4 & others) leading to many drug 
interactions 
 Single dose 200mg is effective in prevention of HIV transmission from 
mother to newborn and is being administered at the time of labour  
 Preferred NNRTI in First line ART (except when patient is on 
Rifampicin containing   ATT for co-infected TB) 
 
EFAVIRENZ 
 Active against HIV-1; Not active against HIV-2 
 Oral bioavailability increased with fat meal 
 Adult dose 600mg at bed time 
 Metabolised by Cytochrome P450 enzyme system; however, Rifampicin 
reduces bioavailability of Efavirenz only by 20%  
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 Preferred during treatment for TB (with Rifampicin);  Adult dose of 
Efavirenz remains the same-600mg 
 Avoid in children: 
 <3 years of age   
 When Body Wt <10 kg 
 CNS toxicity: Vivid dreams, nightmare, dizziness, headache, , 
depression, insomnia, exacerbation of psychiatric disorders, psychosis, 
suicidal ideation hallucination, impaired concentration and attention 
span   
 CNS effects (at least some) are observed during first few doses of 
Efavirenz in >50% of patients 
 Typically starts after 1st and / or 2nd dose of Efavirenz  
 Usually subsides by 2 to 6 weeks 
 Risk factors:  
 Genetic predisposition 
 Use of concomitant drugs with CNS effects  
 Efavirenz is to be taken in empty stomach before night dinner or 
2-3 hours after dinner before going to bed to reduce drug 
concentration and CNS effects 
  Pre-existing  psychiatric illness 
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NNRTI ADVERSE EFFECTS 
DRUG ADVERSE EFFECTS 
ALL NNRTIs Skin rash, hepatitis, CNS manifestations 
NEVIRAPINE Hepatitis,skin rash,steven jhonson syndrome, 
EFAVIRENZ 
Confusion, abnormal thinking, agitation, anxiety. 
Fetal malformation during first four weeks of gestation, 
Gynecomastia in a small proportion of patients. 
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PROTEASE INHIBITORS: 
 Protease Inhibitors prevent splitting of large viral precursor proteins into 
functional core proteins 
 Produce immature, defective, noninfectious viral particles 
 Extensively metabolised by cytochrome P450 enzyme system (CYP3A4 
and others) 
 Atazanavir + Ritonavir or Lopinavir + Ritonavir (Boosted PI is being 
used for Alternate first line ART and Second line ART in India 
 
RITONAVIR BOOSTED PROTEASE INHIBITOr: 
 The primary role of Ritonavir in boosted protease inhibitor regimen is to 
enhance the pharmacokinetics of the second PI  
 It is achieved by inhibiting of CYP3A4. The resultant  increase in Cmax, 
Cmin and AUC of the second Protease inhibitor (Atazanavir or 
Lopinavir) enhance its the therapeutic bioavailability 
 Ritonavir boosted PI (e.g. Atazanavir/ritonavir and Lopinavir/ritonavir) 
regimens have shown high levels of viral load suppression among both 
antiretroviral naïve and prior PI-treated patients 
 Raises the genetic barrier for development of PI resistance 
 Reduces pill burden 
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PROTEASE INHIBITORS SIDE EFFECTS: 
Side effects Management 
Dyslipidemia (hypertriglyceridemia,   
hypercholesterolemia) & 
Lipodystrophy 
Diet, walking, statins, Fenofibrate, 
etc. 
Rise of transaminase (10-12%) 
Screen for HbsAg & anti-HCV &  
monitor LFTs regularly 
Hyperglycemia Diet control, OHA, Insulin 
Increased bleeding episodes in  
Haemophiliacs 
Frequent Factor VIII transfusion 
Osteoporosis, avascular necrosis 
Switching to non-PI based ARV, 
Calcium supplementation 
 
Atazanavir (ATV):  
 Activity against HIV-1; variable activity against HIV-2  
 Administration with food enhances bioavailability  
 Atazanavir is largely metabolised in the liver by cytochrome P450 
(CYP) 3A and inhibits CYP3A and UGT1A1  
 Atazanavir boosted with Ritonavir  
 Dose Atazanavir (300mg) + ritonavir (100mg) OD  
 Renal failure Standard dose can be used except in patients on haemo-
dialysis who should get only boosted atazanavir 
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PI-class specific side-effects:  
 Hyperglycemia, fat maldistribution, hyperlipidemia (especially with 
Ritonavir boosting)  
 Increased bleeding episodes in haemophiliacs  
 Unique side-effects of Atazanavir include  
 Indirect Hyperbilirubinaemia (producing yellow discolouration of 
sclera)  
 Skin rash 
 Nephrolithiasis (rare) 
 Hepatic failure having Child-Pugh Score 7-9, dose is 300mgs once 
daily; avoid with score >9  
 If Indinavir and Atazanavir are taken together can cause Indirect 
hyperbilirubinemia, . Hence, Indinavir should not be co administered 
concomitantly  
 Atazanavir is a Category B drug in Pregnancy (FDA)  
 Atazanavir is not recommended for use in patients less than 6 years of 
age  
 
  
29 
 
 
LOPINAVIR (LPV) 
 Activity against HIV-1 and against HIV-2  
 Lopinavir is extensively metabolised in the liver by cytochrome P450 
(CYP) 3A and inhibits CYP3A and UGT1A1  
 Lopinavir is boosted by co-administered Ritonavir  
 Dose 400 mg of LPV/100mg of RTV twice daily in adults and as per 
weight bands in children 
 Oral LPV/r syrup formulation is available for administration in children; 
should be given with food  
 A high-fat meal increases absorption of this drug, especially of  the 
liquid preparation  
 
Operational Guidelines For Lifelong ART For All Pregnant Women 
Living With HIV To Prevent Mother To Child Transmission Of HIV In 
India. 
 
December 2013 NACO GUIDELINES: 
 The anti retroviral therapy helps the mother by improving her own 
health and also helps in PPTCT programme by reducing the viral load in 
mother and loading the newborn with the virus. Providing Nevirapine syrup to 
newborn upto 6 weeks after birth helps in prohylaxis to the newborn: If a 
woman is newly diagnosed as HIV positive she is started immediately on ART. 
If she is already on a particular regimen of ART the same is continued 
throughout pregnancy. 
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RECOMMENDATIONS FOR HIV POSITIVE PREGNANT WOMEN  
 Pregnant women  newly detected to be HIV positive during  routine 
antenatal check up should be initiated on Anti Retroviral Therapy regardless of 
clinical stage or CD4 count.   
 
 TDF  tenofovir (300mg) + 3TC lamivudine (300mg) + EFV efavirenz 
(600mg )  
 
 Obtain sample for CD4 count before initiating or soon after starting 
ART The initiation of ART should not be delayed for want of CD4 test results. 
 
ART regimen for pregnant women having prior exposure to NNRTI for 
PPTCT 
 Because of the risk of resistance (archived resistance) to NNRTI drugs 
in this population, Efavirenz in the TDF+3TC+EFV regimen may not be 
effective. Thus, these women will require a protease inhibitor-based ART 
regimen    TDF( tenofovir )+ 3TC(lamivudine) + LPV(lopinavir) 
 
 As per PPTCT guidelines, all positive pregnant women exposed to NVP 
in past should be initiated on LPV (lopinavir)/ritonavir instead of EFV.  
 
 The indications for Cotrimoxazole initiation in pregnant women follow 
that for other adults. Cotrimoxazole prophylaxis prevents Opportunistic 
Infections (OIs) such as Pneumocystis jiroveci pneumonia (PCP), 
toxoplasmosis, diarrhoea as well as bacterial infections. 
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 Cotrimoxazole should be given if CD4 count  <250 cells/mm3. It  should 
be continued through pregnancy, delivery and breast-feeding as per national 
guidelines. It should be ensured that the pregnant women takes her folate 
supplements regularly. 
 
INTERVENTIONS DURING LABOUR AND DELIVERY: 
 Minimise vaginal examinations  
 Avoid prolonged labour by using oxytocin to shorten labour  
 Avoid premature rupture of membranes  
            Use partogram to monitor labour 
            Do not use suction unless absolutely necessary  
 Avoid unnecessary trauma during delivery 
o Use non-invasive foetal monitoring 
o Avoid invasive procedures 
o Avoid routine episiotomy 
 Try to avoid the use of forceps or vacuum  
o Avoid Uterine manipulation- external cephalic version (ECV)  
 
 Caesarean section performed prior to the onset of labour and rupture of 
the membrane minimises HIV transmission. 
 
 The risk of elective Caesarean for reducing mother to child transmission 
should be assessed carefully in the context of factors such as, risk of post-
operative complications and Cost 
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In India normal vaginal delivery is recommended unless the woman has 
obstetric indications for a C-section. 
 
 Use of ART can reduce risk of mother to child transmission is better and 
with less risk than a C-section. 
 
For infants: 
 Observe for signs and symptoms of HIV infection 
 All HIV exposed infants should receive cotrimoxazole at 4-6 weeks of 
age 
 Follow standard immunisation schedule 
 Routine well baby visits 
 Early Infant Diagnosis: DNA PCR test  
 18-month visit for HIV antibody testing 
 
Feeding practices: 
 Feeding options must be explained to all the mothers and they must be 
allowed to select their choice  
 Exclusive Replacement feeding (ERF) if Affordable, Feasible, 
Acceptable, Sustainable & Safe 
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Breastfeeding: NACO Recommendations: – 
HIV positive: 
 For these infants, exclusive breast feeding is to be done till 6 months. 
Breast feeding can be continued up to 12 months.  
 
 HIV negative: 
 Exclusive breast feeding is to be done till 6 months and start 
complimentary feeding at 6 months of age. Breastfeeding should continue up 
till 12 months only. Stopping of breast feeding should be done gradually over   
1 month according to the comfort of the mother and child. Educate parents that 
HIV testing needs to be done again after cessation of breastfeeding according 
to the EID protocols.   
 
PROPHYLAXIS FOR HIV EXPOSED INFANTS: 
BIRTH WEIGHT DOSE DURATION 
<2KG 2MG/KG  ONCE A DAY 6 WEEKS 
2-2.5KG 10MG PER DAY 6WEEKS 
>2.5KG 15 MG PER DAY 6WEEKS 
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1) Gestational Diabetes mellitus in a cohort of HIV-1 infected pregnant 
women 
MI Gonzalez Tome and associates, HIV medicine Vol.9, Issue-10, Pages 868-
874, Nov.2008. 
  
 This is  a prospective analytical study conducted in 12 spanish hospitals 
in urban areas of Madrid and Barcelona from may 2000 to December 2003. 
The cohort had 669 HIV positive pregnant women. The aim was to find the 
prevalence of gestational diabetes mellitus (GDM) and associated risk factors 
in these patients. 
 
 None of the mothers had  were on pentamidine corticosteroids or other 
drugs (except ARV) which affects glucose metabolism. Women with 
pregetational diabetes were excluded from the study. A variety of information 
was gathered including clinical events in pregnancy, obstetric and demographic 
details, insulin use, ART history and HIV history 
 
 Additional screening for Hep B, Hep C, rubella, CMV & genital 
infections was done. Screening for GDM using O’Sullivan test at 24-26 hours 
and confirmation with oral glusose challenge test was done. 
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Results 
 The median age was 30.7 years (range 16-44)  At third trimester median 
viral load was 1.910g (range 1.7-5.4) .   and CD4 count  was 545 cells/µl (range 
139-1690 cells) 
 
 74% of patients were on HAART of which 41% were on protease 
inhibitor. 
 
 An above average prevalence of 7% for  GDM  was found  95% 
confidence internal (CI) 5.2-9.5  Risk factors associated with GDM in 
univariate analysis include protease inhibitor exposure hepatitis C co-infection 
older age stavudine  However Protease inhibitor(AOR 2.4, 95%) CI (1-5.3)  
and older age (adjusted to odds ratio (AOR) 1.09, 95% CI (1-1.1)  were proven 
as independent risk factors in multivariate analysis for GDM development. 
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2) Effect of antiretroviral agents on carbohydrate metabolism in HIV-1 
infected pregnant women.  
Patricia E1 Beitune and associates. 
 Diabetes / Metabolism Research and Reviews. Vol 22, Issue 1, Pages 59-63, 
January / February 2006. 
 
 A prospective analytical  study  was conducted on 57 pregnant women  
to find the effect of antiretroviral drugs (ARV) on the carbohydrate metabolism 
in  pregnancy. 
 
 The women were divided into 3 groups ZDV group 20 HIV-1 infected 
women taking zidovudine TT group 25 patients on triple antiretroviral (ZDV + 
3TC + NFV) and control group 12 pregnant women. 
 
 Fasting plasma glucose and OGTT were performed on these patients. 
 
Results 
 The median values of the area under the  curve (AUC)  of glycemic 
values over a period of 120 min between the 33rd and 38th week was 
136.50mg/dL for the TT group(p0.049) 134.77 mg/dL for ZDV group 116.85 
mg/dL for control group  There was an increase in AUC along pregnancy for 
all three groups  regardless of the treatment used although this increase was 
significant only in the TT group (p-0.001) The antiretroviral agents had no 
deleterious effects on low birth weight prematurity on Apgar scores or  
intrauterine growth restriction. 
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Conclusion 
 There was an association noted between the use of protease inhibitors 
and the development of glucose intolerance in pregnancy The antiretroviral 
drugs had no deleterious effect on perinatal prognosis. 
 
3) The AMRO study  Pregnancy outcomes in HIV 1 infected women under 
effective HAART and a policy of vaginal delivery 
 K. Boer, D Patel and associates BJOG, Vol 114, Issue 2, Pg 148-155, Feb 
2007. 
 A cohort of 143  HIV  positive pregnant women including matched case 
control study in a 2:1 ratio of controls to case (n=98) was conducted at 
Academic Medical Centre in Amsterdam and Erasmus Medical Centre in 
Rotterdam from December 1997 to July 2003 All HIV infected women on 
HAART and delivery after 15 weeks were included in the study. 
 Patient characteristics like ethinicity, age, mother’s testing, type of HAART, 
time of inhibition, maternal viral loads, CD4+ count were collected. 
 
Result  
 MTCT was 0% [95% CI (0.2%)]. 78% of HIV-1 positive women had  
commenced  and 62% delivered vaginal delivery Preterm delivery rates were 
18% (95% CI 11-27) in women infected with HIV-1 and 9% (95% CI 5-13) in 
controls (p=0.03) The calculated number of caesarean sections needed to 
prevent single MTCT was 131 or more HAART used at <13 weeks of gestation 
was associated with a 44% preterm delivery rate compared with 21% when 
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HAART was started at or after 13 weeks and 14% in controls incidence of pre-
eclampsia and  Very low birth weight  were not different between HIV1 and 
controls. 
 
4) Improved Obstetric outcomes and few maternal toxicities associated 
with antiretroviral therapy, including highly active antiretroviral therapy 
during pregnancy.  
Juomala, RuthE, Watts D Heather and associates Journal of AIDS, 1 April 
2005, Vol.38, Issue 4, P 449-473 
 
 It was a multicentric, prospective, cohort study of 2543 HIV positive  
pregnant women and their infants that began enrollment in 1989  all singleton 
pregnancies that ended between January 1990 and Feb 2002 were included . 
Delivery >20 weeks of gestation were included. 
 
 Prospective data collected consisted of patient, interviews, standardized 
laboratory data assessment, medical records abstraction, CD4 count and HIV 
viral load were measured. 
 
 Information regarding time of initiation of ART at time of enrollment 
collected. 
 
 The ART regimen used was also noted for each case. 
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Outcome Definitions 
 Maternal complications included gestational diabetes (diagnosed based 
on 3 hr GTT) anemia (Hct <28 or Hb <9.3) thrombocytopenia (Platelet count 
<100000) gastrointestinal toxicities (Pancreatitis, cholecystitis / cholelithiasis, 
esophagitis, gastritis, hyperemesis, hepatitis or abnormal liver function tests in 
absence of chronic hepatitis) neurological toxicities (seizures, subarachnoid 
hemorrhages, subdural hematoma, cerebral atrophy and motor symotoms, renal 
toxicities, dermatological toxicities  lactic acidosis and death obstetric 
complications included hypertensive complications (BP>140/90, albuminuria, 
HELLP) preterm labour, PPROM, preterm delivery, low birth weight, stillbirth. 
 
Statistical Methods 
 Distribution and means of maternal characteristics according to timing 
and type of ART were compared using X2 analysis. ART variables and non 
ART co-variables related to the outcomes were determined through univariate 
analysis using countingency table analyses for categoric exposure variables , 
student t test for continuous variables Logistic regression using a stepwise 
elimination procedure was performed to identify independent predictors of 
each specified outcome 
 
 Odds ratio and 95% CI were obtained from X2 analysis and final logistic 
regression model 
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Results 
 Late use of ART was associated with GDM OR=3.5 95% CI 1.2-10.1  
ART use was associated with anemia OR=1.6  95% CI : 1.1-2.4   There was an  
increase in preterm delivery <37 weeks in 10 women with late use of ART not 
containing zidovidine OR=7.9  95% CI 1.4-44.6 There was a  decrease in 
adverse pregnancy outcome as follows. 
 
Late use ART containing zidovidine associated with decreased stillbirth  
OR=0.06 95% CI 0.02 – 0.18  and preterm delivery at <37 weeks OR=0.5 95% 
CI 0.3-0.8   
 ART containing nucleoside reverse transcriptase  inhibitors but not ZDV 
during early and late pregnancy was associated with decreased risk for Preterm 
delivery at <32 weeks (OR=0.3, 95% CI=0.2-0.7).  
Benefits of ART continue of overweight observed risk. 
 
5) Effect of protease inhibitor therapy on glucose intolerance in pregnancy 
Jang, Jennifer & associated, Obstetrics and Gynaecology May 2006, Vol 107, 
Issue 5.  
  
 The objective of this study was to find if protease inhibitor use was 
associated with increased glucose intolerance in HIV positive  pregnant women  
 
Method :  
  The study included 171 HIV positive pregnant women from January 1, 
1998 to January 8 2004  who had 1 hour and 3 hour glucose test values 
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available History of drug regimens used at the time of glucose testing was 
noted. HIV infected women were then matched 1:3 to HIV non infected 
pregnant women by race, age and 1 year of delivery. 
 
Results:  
 171 HIV women has glucose test available. 12% had an abnormal 1hr 
glucose value  3% had abnormal 3 hour glucose. This was similar to HIV non 
infected women 45% of HIV infected cohort was on protease inhibitor at the 
time of glucose testing. Protease inhibitor exposure has no effect on glucose 
test and HIV infection also had no effect on glucose test results. 
 
6) Pregnancy complications in HIV positive women – 11 year data from 
Frankfurt HIV cohort 
Reitter, Stucker AU, LindeR and associates; HIV med 2014 oct. 
 The aim of this study was to analyse the pregnancy complications in 
HIV positive women and changes in the rates of such complications over 11 
years in Frankfurt  A cohort of  330  HIV positive women between January 1 
2002 to 31 December 2012 were included in this study The incidence of 
pregnancy related complications such as preeclampsia mode of delivery,, 
preterm delivery, gestational diabetes and obstetric history were analysed. 
Maternal and neonatal mortality and morbidity as well as HIV mother to child 
transmission were evaluated. 
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Results: 
 In this study 5 women 1.5% developed preeclampsia Gestational 
diabetes was diagnosed in 38 women 11.4% In 16 women 4.8% preterm  
rupture of membranes (PROM) occurred  46 women were admitted with 
preterm labour Preterm delivery rate was 36.5%  . 26.9% of deliveries (n=90) 
were between 34 weeks and 36+6  weeks  The percentage of women with 
undetectable HIV viral load had increased significantly p<0.001 from 26.1% to 
75% leading to obstetric changes including an increase in rate of vaginal 
deliveries (p<0.001) from no vaginal births to 50%  The preterm delivery rate 
decreased significantly (p<0.501) from 79.2% to 8.3%  There was no 
significant changes in PROM, preeclampsia,GDM  or preterm labour. 
 
7) Gestational Diabetes Mellitus and Dyslipidemia in HIV infected 
pregnant women receiving protease inhibitors based HAART. 
 Nahawut Wetchittichareon, Suvanna A Savapiriyanont. Thai journal of 
Obstetrics and Gynaecology, January 2013, Vol 21, PP 10-15. 
 
 The objective of the study was to find the incidence altered lipid 
metabolism gestational diabetes mellitus (GDM) and birth weight in HIV 
infected pregnant women receiving protease inhibitor based HAART. 
 
 This is a cross sectional descriptive study involving 109 HIV infected 
pregnant women on Protease inhibitor based (Lopinavir / Ritonavir) HAART to 
prevent mother to child transmission at  Rajanithi Hospital  the study was 
conducted from October 2010 to July 2012 A 100g glucose tolerance test was 
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performed in women with abnormal OGCT values during 2nd and 3rd trimester 
and lipid profile was measured after the 4th week of treatment. 
 
The women who had pre-gestational diabetes for those on 
corticosteroids were excluded from the study. 
 
Birth weight, apgar scores and route of delivery were recorded. All 
statistical analysis were performed using SPSS 16.0 software.  
 
Results : 
 The patients mean age was 28.9 years, most (79.8% were have for 
HAART before pregnancy. The incidence of GDM was 7.3%. There was an 
increase in post treatment level of total cholesterol (TC) and triglyceride at 18.9 
mg/dL (95% CI (9.5-28.4) and 97.2 mg/dL (95% CI 70.9 – 123.3) respectively. 
The incidence of low birth weight was 17.4%. 
 
Conclusion: 
 Use of protease inhibitors based HAART in pregnant women was 
associated with increased GDM and altered lipid metabolism. 
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8) Gestational Diabetes Mellitus in HIV infected and uninfected pregnant 
women in Cameroon. 
 Jenifer Goa, Marcia Wong and associated Diabtes care 2013 september 36(9) 
e141-e142. Published online 2013 August. 
 
 A prospective analytical study of  316 pregnant women aged 15-50 
years at a large semiurban clinic in Cameroon was conducted. A 75g OGTT 
was performed at 24-28 weeks or at first prenatal visit for those who came after 
28 weeks Data on height, blood pressure, socio demographic obstetric history, 
pre pregnancy weight, HIV status, anti-retroviral therapy and pregnancy, 
outcomes collected  Exact logistic regression models were used to identify and 
study the variables predicting GDM. 
 
 Of 316 participants 3 had overt diabetes and 20 (6.3%) had GDM. 
Women with GDM presented for OGTT later than those without GDM 
(p=0.04). After adjustments for family history of diabetes gestational age at the 
time of OGTT   pre pregnancy BMI ,age  only age >30 years, remained a 
significant predictor of GDM Among HIV infected women 6.6% (11 of 166) 
exhibited GDM  In this subgroup median age 30.5 vs 28 yrs systolic 118 vs 105 
mmHg and diastolic 76 vs 64mmHg blood pressure and rates of Combined 
ART use during pregnancy  90.9 vs 54.2%  differed significantly between those 
with vs without GDM (P=0.04  0.02  0.02 respectively) 
 
 Overall rate of GDM (6.3%) is comparable with those is developed 
settings These are very much dependent on method and criteria used. The use 
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of combined ART particularly protease inhibitors is associated with GDM in 
pregnancy and non pregnant women The low rates of Combined ART (33 of 
166) and protease inhibitor (1 of 166) use in HIV infected group explains why 
an association between HIV and GDM was not found in this study. 
 
 Among  HIV infected group GDM was associated with high blood 
pressure. Almost all (91%) of the HIV infected women with GDM were on 
Combined ART. 
 
 Nonetheless, the significant association between Combined ART and 
GDM in univariate analysis is consisted with reports in developed countries. 
 
  
Observation & Results 
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STATISTICS 
 
TABLE 1: PARITY AND GDM 
 
 
GDM  
NO YES Total 
Gravid 
1 
Count 52 2 54 
% within gravid 96.3% 3.7% 100.0% 
% within gdm 57.8% 20.0% 54.0% 
% of Total 52.0% 2.0% 54.0% 
2 
Count 34 5 39 
% within gravid 87.2% 12.8% 100.0% 
% within gdm 37.8% 50.0% 39.0% 
% of Total 34.0% 5.0% 39.0% 
3 
Count 4 2 6 
% within gravid 66.7% 33.3% 100.0% 
% within gdm 4.4% 20.0% 6.0% 
% of Total 4.0% 2.0% 6.0% 
4 
Count 0 1 1 
% within gravid .0% 100.0% 100.0% 
% within gdm .0% 10.0% 1.0% 
% of Total .0% 1.0% 1.0% 
 Total 
Count 90 10 100 
% within gravid 90.0% 10.0% 100.0% 
% within gdm 100.0% 100.0% 100.0% 
% of Total 90.0% 10.0% 100.0% 
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Chi-Square Tests 
 Value df Asymp. Sig. (2-sided) 
Pearson Chi-Square 15.353a 3 .002 
Likelihood Ratio 10.399 3 .015 
Linear-by-Linear Association 11.185 1 .001 
N of Valid Cases 100   
a. 4 cells (50.0%) have expected count less than 5.  
The minimum expected count is .10. 
 
 
 
 Table1 shows that as the parity increases there is a steady increase in the 
risk for GDM, primigravida has a risk of 3.7%,second gravida 12.8%, third 
gravida 33.3%, fourth gravid is almost 100%. The P value is <0.05( 0.015) 
satistically significant 
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TABLE 2: LIVE BIRTH 
 
 
GDM  
0 1 Total 
live birth 
0 
Count 62 3 65 
% within live birth 95.4% 4.6% 100.0% 
% within gdm 68.9% 30.0% 65.0% 
% of Total 62.0% 3.0% 65.0% 
1 
Count 27 6 33 
% within live birth 81.8% 18.2% 100.0% 
% within gdm 30.0% 60.0% 33.0% 
% of Total 27.0% 6.0% 33.0% 
2 
Count 1 1 2 
% within live birth 50.0% 50.0% 100.0% 
% within gdm 1.1% 10.0% 2.0% 
% of Total 1.0% 1.0% 2.0% 
 Total 
Count 90 10 100 
% within live birth 90.0% 10.0% 100.0% 
% within gdm 100.0% 100.0% 100.0% 
% of Total 90.0% 10.0% 100.0% 
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Chi-Square Tests 
 Value df Asymp. Sig.  (2-sided) 
Pearson Chi-Square 8.104a 2 .017 
Likelihood Ratio 6.637 2 .036 
Linear-by-Linear Association 7.447 1 .006 
N of Valid Cases 100   
a. 3 cells (50.0%) have expected count less than 5. 
The minimum expected count is .20. 
 
 
 Table 2 shows that as the number of living children increases the risk for 
GDM also increases. It is 4.6% in primigravida and 50% in multigravida. P 
value is 0.036 (<0.05) statistically significant. 
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TABLE 3 :   PREVIOUS IUD/STILL BIRTH 
 
 
GDM 
Total 
NO YES 
IUD/STILL 
NO 
Count 89 8 97 
% within IUD/STILL 91.8% 8.2% 100.0% 
% within gdm 98.9% 80.0% 97.0% 
% of Total 89.0% 8.0% 97.0% 
YES 
Count 1 2 3 
% within IUD/STILL 33.3% 66.7% 100.0% 
% within gdm 1.1% 20.0% 3.0% 
% of Total 1.0% 2.0% 3.0% 
 Total 
Count 90 10 100 
% within IUD/STILL 90.0% 10.0% 100.0% 
% within gdm 100.0% 100.0% 100.0% 
% of Total 90.0% 10.0% 100.0% 
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Chi-Square Tests 
 Value df 
Asymp. 
Sig. (2-
sided) 
Exact Sig. 
(2-sided) 
Exact Sig. 
(1-sided) 
Pearson Chi-Square 11.035a 1 .001   
Continuity 
Correctionb 5.498 1 .019   
Likelihood Ratio 5.952 1 .015   
Fisher's Exact Test    .026 .026 
Linear-by-Linear 
Association 10.924 1 .001   
N of Valid Cases 100     
a. 2 cells (50.0%) have expected count less than 5.  
The minimum expected count is .30. 
b. Computed only for a 2x2 table 
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 This table shows that the risk of GDM with previous IUD or still birth is 
increased to 66.7%. The P value is <0.05%(0.015) which is statistically 
significant. 
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TABLE 4  :  PREV GDM 
 
 
 
GDM  
NO YES Total 
PREV GDM 
No 
Count 89 7 96 
% within PREV GDM 92.7% 7.3% 100.0% 
% within gdm 98.9% 70.0% 96.0% 
% of Total 89.0% 7.0% 96.0% 
Yes 
Count 1 3 4 
% within PREV GDM 25.0% 75.0% 100.0% 
% within gdm 1.1% 30.0% 4.0% 
% of Total 1.0% 3.0% 4.0% 
 Total 
Count 90 10 100 
% within PREV GDM 90.0% 10.0% 100.0% 
% within gdm 100.0% 100.0% 100.0% 
% of Total 90.0% 10.0% 100.0% 
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Chi-Square Tests 
 Value df 
Asymp. 
Sig. (2-
sided) 
Exact Sig. 
(2-sided) 
Exact Sig. 
(1-sided) 
Pearson Chi-Square 19.560a 1 .000   
Continuity 
Correctionb 12.760 1 .000   
Likelihood Ratio 10.383 1 .001   
Fisher's Exact Test    .003 .003 
Linear-by-Linear 
Association 19.365 1 .000   
N of Valid Cases 100     
a. 2 cells (50.0%) have expected count less than 5. 
The minimum expected count is .40. 
b. Computed only for a 2x2 table 
 
 
 
 
 
 
 
55 
 
 
 
 
 
 This table shows that the risk of GDM  increases by 75% if there is a 
previous history of GDM.The P value is 0.001(<0.05) statistically significant. 
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TABLE 5 : BMI>30 * GDM 
 
 
GDM 
Total 
0 1 
BMI&gt;30 
0 
Count 88 8 96 
% within BMI&gt;30 91.7% 8.3% 100.0% 
% within gdm 97.8% 80.0% 96.0% 
% of Total 88.0% 8.0% 96.0% 
1 
Count 2 2 4 
% within BMI&gt;30 50.0% 50.0% 100.0% 
% within gdm 2.2% 20.0% 4.0% 
% of Total 2.0% 2.0% 4.0% 
 Total 
Count 90 10 100 
% within BMI&gt;30 90.0% 10.0% 100.0% 
% within gdm 100.0% 100.0% 100.0% 
% of Total 90.0% 10.0% 100.0% 
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Chi-Square Tests 
 Value df 
Asymp. 
Sig. (2-
sided) 
Exact Sig. 
(2-sided) 
Exact Sig. 
(1-sided) 
Pearson Chi-Square 7.407a 1 .006   
Continuity 
Correctionb 3.501 1 .061   
Likelihood Ratio 4.399 1 .036   
Fisher's Exact Test    .049 .049 
Linear-by-Linear 
Association 7.333 1 .007   
N of Valid Cases 100     
a. 2 cells (50.0%) have expected count less than 5.  
The minimum expected count is .40. 
b. Computed only for a 2x2 table 
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 This table shows that the risk of GDM increases by 50% if BMI is 
greater than 30. P value is 0.036 (<0.05) which is statistically significant. 
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Table 6:1ST RELATIVE * gdm 
 
 
GDM  
0 1 Total 
1ST 
RELATIVE 
0 
Count 79 4 83 
% within 1ST 
RELATIVE 95.2% 4.8% 100.0% 
% within gdm 87.8% 40.0% 83.0% 
% of Total 79.0% 4.0% 83.0% 
1 
Count 11 6 17 
% within 1ST 
RELATIVE 64.7% 35.3% 100.0% 
% within gdm 12.2% 60.0% 17.0% 
% of Total 11.0% 6.0% 17.0% 
 Total 
Count 90 10 100 
% within 1ST 
RELATIVE 90.0% 10.0% 100.0% 
% within gdm 100.0% 100.0% 100.0% 
% of Total 90.0% 10.0% 100.0% 
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Chi-Square Tests 
 Value Df 
Asymp. 
Sig. (2-
sided) 
Exact Sig. 
(2-sided) 
Exact Sig. 
(1-sided) 
Pearson Chi-Square 14.560a 1 .000   
Continuity 
Correctionb 11.371 1 .001   
Likelihood Ratio 10.878 1 .001   
Fisher's Exact Test    .001 .001 
Linear-by-Linear 
Association 14.415 1 .000   
N of Valid Cases 100     
a. 1 cells (25.0%) have expected count less than 5.  
The minimum expected count is 1.70. 
b. Computed only for a 2x2 table 
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 Presence of a first degree relative with diabetes increases the risk of 
GDM by 35.3% 
 
 P value is <0.05(0.001) which is statistically significant. 
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TABLE 7  :  BWT.4KG * GDM 
 
GDM 
TOTAL 
0 1 
BWT.4KG 
0 
Count 89 8 97 
% within BWT.4KG 91.8% 8.2% 100.0% 
% within gdm 98.9% 80.0% 97.0% 
% of Total 89.0% 8.0% 97.0% 
1 
Count 1 2 3 
% within BWT.4KG 33.3% 66.7% 100.0% 
% within gdm 1.1% 20.0% 3.0% 
% of Total 1.0% 2.0% 3.0% 
 Total 
Count 90 10 100 
% within BWT.4KG 90.0% 10.0% 100.0% 
% within gdm 100.0% 100.0% 100.0% 
% of Total 90.0% 10.0% 100.0% 
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Chi-Square Tests 
 Value Df Asymp. Sig. (2-sided) 
Exact Sig. 
(2-sided) 
Exact Sig. 
(1-sided) 
Pearson 
Chi-Square 11.035
a 1 .001   
Continuity 
Correctionb 5.498 1 .019   
Likelihood 
Ratio 5.952 1 .015   
Fisher's 
Exact Test    .026 .026 
Linear-by-
Linear 
Association 
10.924 1 .001   
N of Valid 
Cases 100     
a. 2 cells (50.0%) have expected count less than 5. 
The minimum expected count is .30. 
b. Computed only for a 2x2 table 
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 A previous baby with birth weight >4 kg increases the risk of GDM by 
66.7% . P value is 0.015( <0.05) which is statistically significant. 
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TABLE8  :  ARV REGIMEN * GDM 
 
 
 
GDM 
Total 
0 1 
ARV 
REGIMEN 
TL/Lpr 
Count 1 0 1 
% within ARV 
REGIMEN 100.0% .0% 100.0% 
% within gdm 1.1% .0% 1.0% 
% of Total 1.0% .0% 1.0% 
TLE 
Count 72 9 81 
% within ARV 
REGIMEN 88.9% 11.1% 100.0% 
% within gdm 80.0% 90.0% 81.0% 
% of Total 72.0% 9.0% 81.0% 
ZLN 
Count 17 1 18 
% within ARV 
REGIMEN 94.4% 5.6% 100.0% 
% within gdm 18.9% 10.0% 18.0% 
% of Total 17.0% 1.0% 18.0% 
 Total 
Count 90 10 100 
% within ARV 
REGIMEN 90.0% 10.0% 100.0% 
% within gdm 100.0% 100.0% 100.0% 
% of Total 90.0% 10.0% 100.0% 
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Chi-Square Tests 
 Value df Asymp. Sig. (2-sided) 
Pearson Chi-Square .617a 2 .734 
Likelihood Ratio .782 2 .676 
N of Valid Cases 100   
a. 3 cells (50.0%) have expected count less than 5. 
The minimum expected count is .10. 
 
 
 
 11.1% of patients on TLE developed GDM and 5.6% of patients on 
ZLN had GDM. Occurence of GDM had no statistical significance [pvalue 
0.782( >0.05)] with the occurrence of GDM  in these patients. 
67 
 
 
Table09:Outcome of this pregnancy: 
 
 
 
GDM 
Total 
0 1 
Outcome 
ALIVE 
Count 89 7 96 
% within outcome 92.7% 7.3% 100.0% 
% within gdm 98.9% 70.0% 96.0% 
% of Total 89.0% 7.0% 96.0% 
IUD 
Count 1 1 2 
% within outcome 50.0% 50.0% 100.0% 
% within gdm 1.1% 10.0% 2.0% 
% of Total 1.0% 1.0% 2.0% 
STILL 
BIRTH 
Count 0 2 2 
% within outcome .0% 100.0% 100.0% 
% within gdm .0% 20.0% 2.0% 
% of Total .0% 2.0% 2.0% 
 Total 
Count 90 10 100 
% within outcome 90.0% 10.0% 100.0% 
% within gdm 100.0% 100.0% 100.0% 
% of Total 90.0% 10.0% 100.0% 
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Chi-Square Tests 
 Value df Asymp. Sig. (2-sided) 
Pearson Chi-Square 22.338a 2 .000 
Likelihood Ratio 12.109 2 .002 
N of Valid Cases 100   
a. 4 cells (66.7%) have expected count less than 5. 
The minimum expected count is .20. 
 
 
 
 
 
 The oucome of this pregnancy patients who had live births the risk of 
GDM was found to be 7.3%, With IUD risk was 50%  and with still birth it was 
100% 
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Group Statistics  
 gdm N Mean Std. Deviation 
Std. Error 
Mean P 
AGE 
1 10 29.10 3.315 1.048  
0 90 25.37 2.996 .316  
BMI 
1 10 27.850000 3.6338685 1.1491301  
0 90 23.603333 2.5117007 .2647565  
CD4 
COUNT 
1 10 699.40 234.479 74.149  
0 90 628.11 191.601 20.197  
WEIGHT 
GAIN 
1 10 9.800000 1.3165612 .4163332  
0 90 8.633333 1.4581040 .1536977  
 
 
Independent Samples Test
  Levene's Test for Equality of Variances 
t-test for Equality of 
Means 
    
  F Sig. t df 
AGE 
Equal variances 
assumed .024 .877 3.700 98 
Equal variances not 
assumed   3.410 10.699 
BMI 
Equal variances 
assumed 3.457 .066 4.835 98 
Equal variances not 
assumed   3.601 9.978 
CD4 
COUNT 
Equal variances 
assumed .129 .720 1.092 98 
Equal variances not 
assumed   .928 10.379 
WEIGHT 
GAIN 
Equal variances 
assumed .799 .374 2.421 98 
Equal variances not 
assumed   2.629 11.599 
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LOGISTIC REGRESSION: 
 
Model if Term Removeda 
Variable Model Log Likelihood 
Change in -2 
Log 
Likelihood 
df Sig. of the Change 
Step 1 
WEIGHTGAIN -19.372 9.703 1 .002 
gravida -14.769 .497 1 .481 
IUDSTILL -16.536 4.032 1 .045 
outcome -19.190 9.340 2 .009 
PREVGDM -14.719 .397 1 .529 
@1STRELATIVE -20.646 12.251 1 .000 
Step 2 
WEIGHTGAIN -20.446 11.468 1 .001 
gravida -15.295 1.168 1 .280 
IUDSTILL -17.080 4.738 1 .030 
outcome -19.904 10.385 2 .006 
@1STRELATIVE -20.824 12.225 1 .000 
Step 3 
WEIGHTGAIN -21.744 12.944 1 .000 
IUD/STILL BIRTH -19.378 8.213 1 .004 
outcome -21.485 12.427 2 .002 
@1STRELATIVE -20.645 10.746 1 .001 
a. Based on conditional parameter estimates 
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Variables in the Equation 
  B S.E. Wald df Sig. Exp(B) 
Step 
3a 
WEIGHTGAIN 1.278 .539 5.622 1 .018 3.588 
IUDSTILL 4.492 1.843 5.941 1 .015 89.299 
outcome   .368 2 .832  
outcome(1) -25.048 26043.464 .000 1 .999 .000 
outcome(2) -24.053 26043.465 .000 1 .999 .000 
@1STRELATIVE 2.907 1.087 7.155 1 .007 18.298 
Constant 8.866 26043.465 .000 1 1.000 7085.182
a. Variable(s) entered on step 1: WEIGHTGAIN, gravida, IUDSTILL, outcome, 
PREVGDM, @1STRELATIVE. 
 
 We have done  the  multivariate binary logistic regression analysis and 
found that  previous IUD/STILL birth, Weightgain in the present pregnancy 
and Ist degree  relative were significant associated risk variables in predicting 
the outcome with their Odds ratio as follows: 
 
1. Weight  gain    -   odds  ratio  3.588 
2. IUD still  - odds  ratio 89.299 
3. 1st relative    - odds ratio  18.298 
  
Discussion 
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DISCUSSION 
 100 antenatal patients on antiretroviral therapy were taken in this 
study. 
 
            The overall incidence of GDM came to 11% in my study. Seshiah 
et al [17 ]      conducted a study for prevalence of GDM  in Chennai ,results 
were as follows ;17.8%  in urban,13.8% semiurban,9.9% rural. 
 
 The maternal risk factors that could have been the cause for GDM 
were analysed.   
 
 PARITY: Out of 54 primigravida only 2 had GDM (i.e.) 3.7%, 
second gravida were a  total of 39 patients of which 5 women 
(12.8%) had GDM, and 3rd gravida out of 6 patients 2 had GDM 
(33.3%). We had one 4th gravid and she had GDM (100%). Chi 
square test showed a p-value of 0.015 (p<0.05) which was 
statistically significant ,similar to findings of seshiah  et al .[17] 
 
 As the number of living children increase, the risk of GDM 
increases, in primigravida the risk was 4.6% and in mulligravida it 
was 68.2%. pvalue 0.036 (<0.05) statistical significant. 
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 PREVIOUS IUD/STILL BIRTH : Is a well known risk factor for 
GDM. In my study I had 3 patients with history of  IUD / still birth 
of which 2 women had GDM (66.7%) The p-value came to 0.015 
(<0.05) statistically significant.McMahon et al [39] found previous 
still birth as a significant risk factor[RR 1.8,95% CI 1.08-3.01] 
 
  PREVIOUS GDM: Of 4 patients with a history of previous GDM, 
3 patients 75% had recurrent GDM. The p-value by chi square test 
cause to 0.001% (<0.05) statistically significant. Stephanie mac 
neill et al 35.6% [95% CI=31.9-39.3%] rate of recurrence  of 
GDM[38] 
 
  OBESITY BMI >30 :Of 4 patients with BMI >30, 2 patients had 
GDM (50%) Chi square tests shows p-value of 0.036 
(0.05).Seshiah et al [17] prevalence of GDM highest if BMI>= 
25Kg/m2, 28.4% in urban,23.8%in semiurban and 16.1% in rural. 
The prevalence of GDM in his study was 75% more in women 
with BMI>=25 than in women with BMI 23-24.9 
 
 FAMILY HISTORY: 17 Patients had 1st degree relative with 
diabetes of which 6 patients (35.3%) had GDM. P-value by chi 
square tests is 0.001 (p<0.05) which is statistically significant. 
74 
 
 
Similar to findings of Seshiah et al[17]family history of diabetes was 
a significant risk factor for GDM. 
 
  PREVIOUS BIG BABY: A history of big baby (Bwt >4kg) is a 
proven risk factor for GDM. In my study, 3 patients had history of 
previous baby birth weight >4kg of which 2 patients had GDM in 
this pregnancy. The risk is 66.7% p value is 0.015 (>0.05) which is 
statistically significant. Similar to findings of McMahon et al [39] 
 
  The 100 patients in my study, fall into 3 different antiretroviral 
regimens.  
 
 Tenofovir, Lamivudine, Lopinavir – 1 patient,  
 
 Tenofovir, Lamivudine ,Efavirenz - Had majority patients, 81 
patients of which 9 had GDM (11.1%)  
 
 Zidovidine, lamivudine, Nevrapine 18 patients of which 1 patient 
(5.6%) had GDM. 
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Nattawut et al [14] in his study of 109 patients on protease inhibitor based 
HAART had a an incidence of 7.3% of GDM 
 
 As the protease based inhibitors is no longer in use after the 
introduction of new regimen, newer studies with these drugs are still 
awaited. 
 
 There was no significant association between GDM ( P value 
0.782)and the regimens used in my study. 
 
 The outcome of this pregnancy in the 100 patients under study can 
be summarised as follows; 
 
 96 patients had live birth of which 7 patients (7.3%risk) had GDM. 
 2 patients had IUD of which 1 patient (50% risk) had GDM and 2 
patients had still birth of which both the patient  (100%) had GDM. 
 The mean age of patients with GDM is 29.10 yrs (S.D. + 3.3)( 
Robin vergeese et al [37]median age 27.62+-3.864) and the mean 
BMI is 27.85 (SD + 3.633)[ Robin vergeese et al  [37]mean BMI 
27.89+3.48 Kg/m2 ] 
 The mean weight gain in patients with GDM is  9.8kg (Robin 
vergeese et al [37]   in his study found  57.65%(128women) of 222 
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GDM mothers had weight gain between 10 to 20 kg) and the mean 
CD4 count for patients with GDM is 699.40(.Gonzlez et[1] al 
545cells/microlitre) 
 The univarite analysis shows statistical significance between GDM 
and parity, previous history of GDM, previous birth weight >4 kg, 
BMI >30, previous IUD / Still births and a 1st degree relative with 
GDM. 
 Multivariate analysis (logistic regression) was used and it was 
found that previous IUD/still birth (OR=89.299), present 
pregnancy weight gain (OR=3.588) and 1st degree relative with 
diabetes (OR=18.298) were significant associated with variables in 
predicting the occurrence of GDM.  
 
  
Conclusion 
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CONCLUSION 
 
 There  is no significant increase in the overall incidence of GDM in 
HIV patients.   
 Statistically, there is no significant association between the 
antiretroviral drugs used in my study and the GDM incidence 
(p>0.05) 
 But the 11% incidence of GDM could be explained due to various 
other risk factors associated with GDM which include obesity, 
history of GDM in previous pregnancy, history of IUD/still birth 
and others mentioned in my study. 
 By logistic regression, my study has proven that a history of 1st 
degree relative with diabetes, previous IUD/still birth and weight 
gain in this pregnancy are significant variables contributing to 
GDM in the 11 patients in my study. 
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0 10 ZLN 86 84 105 
 
LSCS 
 
2.95 
   
5 16318 rekha 22 G2A1 23.3 340 18.1.13 ALIVE 21.9.14 
     
0 10.5 TLE 85 95 92 
 
LSCS 
 
3.1 
   
6 17048 srilekha 24 G2P1L1 26.4 457 28.2.13 ALIVE 22.9.14 
     
0 11.5 TL/Lpr 84 90 78 
 
LSCS 
 
1.75 
   
7 17461 manjula 26 G2P1L1 24.4 538 23.3.13 ALIVE 26.9.14 
     
0 11 TLE 70 82 76 
 
NVD 
 
2.760 
   
8 17980 Devi 27 PRIMI 20.7 670 26.2.13 ALIVE 30.9.14 
     
0 8 TLE 75 74 84 
 
NVD 
 
2.200 
   
9 18004 rekha 23 PRIMI 24.4 893 22.3.13 ALIVE 30.9.14 
  
YES 
  
1 10 ZLN 86 84 90 
 
NVD 
 
2.5 
   
10 18093 indhra 25 G2A1 22.8 1017 15.1.13 ALIVE 3.10.14 
     
0 10 TLE 75 74 80 
 
LSCS 
 
3.25 
   
11 19218 karpagam 25 PRIMI 24.6 644 24.2.13 ALIVE 7.10.14 
     
0 11.4 ZLN 90 88 92 
 
LSCS 
 
3.100 
   
12 19522 bhavani 32 
G3P1L1
A1 
28.6 828 24.3.13 IUD 8.10.14 YES 
   
YE
S 
1 12.5 TLE 102 153 
 
insulin ftnvd 
 
4.2 
  
80 
13 19711 sajitha 26 PRIMI 19.7 85 22.2.13 ALIVE 
10.10.1
4      
0 7.4 TLE 90 85 84 
 
NVD 
 
2.750 
   
14 19860 vanisri 22 PRIMI 24.3 430 20.4.13 ALIVE 
13.10.1
4   
YES 
  
1 10.5 TLE 82 90 85 
 
NVD 
 
2.400 
   
15 19932 swapna 19 PRIMI 20.4 458 18.3.13 ALIVE 
15.10.1
4      
0 9.8 TLE 75 70 76 
 
LSCS 
 
2.950 
   
16 20017 renuga 29 G2P1L1 23.6 645 25.4.13 ALIVE 
20.10.1
4      
0 9 TLE 80 75 70 
 
LSCS 
 
3.150 
   
17 20081 dhivya 27 G2P1L1 30.4 736 13.4.13 ALIVE 
23.10.1
4  
YE
S    
1 10 TLE 75 80 82 
 
LSCS 
 
2.800 
   
18 20102 
mariyamm
al 
28 G2P1L1 29.3 658 6.5.13 ALIVE 
26.10.1
4   
YES 
  
1 10 TLE 126 147 
 
INSULI
N 
LSCS 
 
3.9 
  
85 
19 20116 logeshwari 26 PRIMI 22.4 347 10.4.13 ALIVE 
29.10.1
4      
0 8.5 TLE 80 84 86 
 
NVD 
 
2.400 
   
20 20180 rehnaz 33 G3P2L2 27.2 472 23.4.13 ALIVE 
30.10.1
4   
YES 
  
1 8.5 TLE 74 90 84 
 
NVD 
 
2.890 
   
21 21057 malliga 21 primi 22.1 649 20.5.13 ALIVE 3.11.14 
     
0 9.5 ZLN 85 96 104 
 
NVD 
 
3.100 
   
22 21088 
vijaylaksh
mi 
28 G2P1L1 24.2 631 4.5.13 ALIVE 9.11.14 
     
0 7.5 TLE 95 96 94 
 
LSCS 
 
3.50 
   
23 21134 Sony 32 G2P1L1 22.6 834 22.5.13 ALIVE 
12.11.1
4      
0 7 TLE 75 76 80 
 
NVD 
 
2.600 
   
24 21196 suganthi 26 PRIMI 21.2 731 12.5.13 ALIVE 
17.11.1
4      
0 8 TLE 80 74 76 
 
NVD 
 
2.550 
   
25 21200 Devi 23 PRIMI 25.3 640 5.5.13 ALIVE 
18.11.1
4      
0 9.5 TLE 92 90 86 
 
NVD 
 
2.450 
   
26 21249 sangeetha 28 G2P1L1 22.3 452 25.5.13 ALIVE 
22.11.1
4      
0 8 TLE 80 92 94 
 
NVD 
 
3.200 
   
27 21273 nithya 25 PRIMI 21.8 783 7.3.13 ALIVE 
23.11.1
4      
0 7 ZLN 93 94 102 
 
NVD 
 
3.00 
   
28 21337 aishwarya 27 G2A1 21.4 932 12.5.13 ALIVE 
26.11.1
4      
0 9 TLE 78 90 79 
 
NVD 
 
3.100 
   
29 21381 
senthamar
ai 
25 G2P1L1 23.7 614 10.5.13 ALIVE 
30.11.1
4   
YES 
  
1 9.5 TLE 66 86 80 
 
NVD 
 
2.900 
   
30 21440 anitha 27 PRIMI 23.5 792 20.5.13 ALIVE 1.12.14 
     
0 7 TLE 84 78 80 
 
NVD 
 
2.400 
   
31 21593 umarani 29 G2P1L0 22.6 656 24.5.13 ALIVE 2.12.14 
  
YES YES 
 
1 8 TLE 154 
  
MEAL LSCS 
 
3.1 
  
84 
32 21609 usha 30 G4P3L2 21.7 734 17.6.13 ALIVE 5.12.14 yes 
 
YES YES 
 
1 8.5 ZLN 142 
  
MEAL FTNVD 
 
3.2 
  
70 
33 1612 puppy 22 G2P1L0 23.2 722 20.6.13 ALIVE 
13.12.1
4    
YES 
 
1 8.5 TLE 90 94 90 
 
NVD YES 2.220 
   
34 16206 latha devi 23 G2P1L1 22.8 139 12.6.13 ALIVE 
17.12.1
4      
0 7.5 TLE 85 80 86 
 
NVD 
 
2.50 
   
35 21677 
murugam
mal 
21 PRIMI 19.3 741 19.4.13 ALIVE 
19.12.1
4      
0 6.5 TLE 84 90 92 
 
LSCS 
 
2.750 
   
36 21702 
darisanad
evi 
32 PRIMI 22.9 540 2.6.13 ALIVE 
23.12.1
4      
0 7.5 ZLN 78 82 87 
 
NVD 
 
2.360 
   
37 21767 srilekha 20 PRIMI 20.1 649 26.5.13 ALIVE 
26.12.1
4      
0 8 TLE 90 94 95 
 
NVD 
 
2.500 
   
38 21804 ammu 21 PRIMI 20.6 637 20.5.13 ALIVE 
27.12.1
4      
0 7 TLE 86 82 78 
 
LSCS 
 
3.100 
   
39 21860 sathya 27 G2P1L1 24.3 953 23.7.14 ALIVE 3.1.15 YES 
    
1 9.5 TLE 65 72 70 
 
LSCS 
 
3.450 
   
40 22004 gloriya 21 PRIMI 21.7 600 14.7.14 ALIVE 5.1.15 
  
YES 
  
0 8 ZLN 78 70 65 
 
NVD 
 
3.00 
   
41 22136 nathiya 27 PRIMI 23.8 742 23.8.14 ALIVE 11.1.15 
     
0 7.5 TLE 70 76 74 
 
NVD 
 
3.200 
   
42 22362 jansi 22 PRIMI 22.1 683 3.8.14 ALIVE 15.1.15 
     
0 7.5 TLE 86 90 92 
 
NVD 
 
2.450 
   
43 22474 lakshmi 34 G2P1L1 29.8 722 23.8.14 ALIVE 16.1.15 
     
0 11 TLE 95 155 
 
MEAL FTNVD 
 
3.12 
  
80 
44 22576 
punithavat
hy 
26 PRIMI 23.9 651 13.8.14 ALIVE 21.1.15 
     
0 7.5 TLE 72 70 74 
 
NVD 
 
2.910 
   
45 22601 saranya 27 PRIMI 27.5 346 22.8.14 ALIVE 23.1.15 
     
0 8 TLE 68 74 75 
 
LSCS 
 
2.850 
   
46 23008 revathy 25 PRIMI 23.2 728 19.8.14 ALIVE 25.1.15 
     
0 8.5 TLE 92 90 84 
 
NVD 
 
3.200 
   
47 23197 nancy 29 G2P1L1 31 244 15.8.14 ALIVE 25.1.15 
  
YES 
  
1 10 TLE 86 146 
 
INSULI
N 
LSCS 
 
3.5 
  
82 
48 23215 baby 25 PRIMI 23.6 326 6.8.14 ALIVE 27.1.15 
     
0 9 TLE 80 84 86 
 
NVD 
 
2.800 
   
49 23293 brindha 26 G3A2 24.5 469 27.7.14 ALIVE 30.1.15 
     
0 10 TLE 75 80 84 
 
NVD 
 
2.600 
   
50 24009 shanthy 29 G2P1L1 30.9 185 20.7.14 ALIVE 31.1.15 
 
yes 
   
1 6 TLE 76 89 108 
 
NVD YES 1.8 
   
51 24343 kumari 24 PRIMI 19.1 673 12.8.14 ALIVE 2.2.15 
     
0 6.5 TLE 76 80 76 
 
NVD 
 
2.700 
   
52 24399 
prasannad
evi 
29 G2P1L1 25.6 842 28.8.14 ALIVE 7.2.15 
     
0 8.5 ZLN 84 83 90 
 
LSCS 
 
3.3 
   
53 25087 merloando 26 G2A1 23.9 936 6.8.14 ALIVE 9.2.15 
     
0 8 TLE 95 104 110 
 
NVD 
 
3.100 
   
54 24706 sharmila 24 PRIMI 22.6 737 26.8.14 ALIVE 11.2.15 
     
0 7 TLE 86 95 98 
 
NVD 
 
3.250 
   
55 26259 sumandevi 29 G2P1L1 23.1 491 15.8.14 ALIVE 11.2.15 
     
0 7.5 TLE 84 90 94 
 
NVD 
 
2.450 
   
56 26702 gowshiya 21 PRIMI 20.6 781 25.8.14 ALIVE 15.2.15 
  
YES 
  
1 6 TLE 78 86 87 
 
NVD 
 
2.500 
   
57 26901 sumathy 30 G2P1L1 27.8 603 28.8.14 ALIVE 23.2.15 
     
0 8.5 TLE 92 96 95 
 
NVD 
 
2.600 
   
58 27352 sumandevi 24 PRIMI 23.5 577 24.8.14 ALIVE 27.2.15 
     
0 8 TLE 75 80 84 
 
NVD 
 
2.400 
   
59 27471 sharmila 25 PRIMI 27.3 765 20.8.14 ALIVE 1.3.15 
     
0 9.5 ZLN 80 86 90 
 
LSCS 
 
2.950 
   
60 27783 rathi 27 PRIMI 24.6 733 28.8.14 ALIVE 2.3.15 
     
0 8.5 TLE 66 70 74 
 
LSCS 
 
3.200 
   
61 28194 kamatchi 32 PRIMI 30.2 780 3.9.14 ALIVE 6.3.15 
     
0 10 TLE 89 85 95 
 
NVD 
 
3.300 
   
62 28553 devi 22 PRIMI 23.7 317 21.9.14 IUD 10.3.15 
  
YES 
  
1 9 ZLN 70 75 76 
 
NVD 
 
3.250 
   
63 28903 lakshmi 21 PRIMI 22.5 960 11.9.14 ALIVE 11.3.15 
     
0 9.5 TLE 80 85 75 
 
NVD 
 
2.750 
   
64 29112 christi 26 G2P1L1 26.2 650 22.9.14 ALIVE 15.3.15 
     
0 11 TLE 75 80 84 
 
LSCS 
 
3.250 
   
65 30035 aruna 22 PRIMI 20.3 844 27.9.15 ALIVE 16.3.15 
     
0 7.5 TLE 86 128 96 
 
NVD 
 
3.00 
   
66 30209 berenice 27 PRIMI 32 1032 1.9.14 ALIVE 21.3.15 
 
YE
S    
1 10.5 TLE 155 
  
INSULI
N 
FTLSCS 
 
3.6 
  
80 
67 30411 manjula 28 G2P1L1 25.7 370 14.9.14 ALIVE 24.3.15 
    
ye
s 
1 7 TLE 82 84 84 
 
NVD 
 
2.750 
   
68 30525 preethi 22 PRIMI 19.6 637 1.9.14 ALIVE 31.3.15 
     
0 6 TLE 98 90 96 
 
NVD 
 
2.850 
   
69 31196 sandiya 25 G2P1L1 23.8 936 28.9.14 ALIVE 3.4.15 
     
0 7.5 TLE 125 98 115 
 
NVD 
 
3.1 
   
70 32007 sudandra 24 PRIMI 24.5 778 23.9.14 ALIVE 5.4.15 
     
0 8.5 ZLN 97 102 112 
 
NVD 
 
2.5 
   
71 32960 banupriya 25 
G2 
P1L1 
23.3 420 21.9.14 ALIVE 6.4.15 
  
YES 
  
1 7.5 TLE 84 96 110 
 
NVD 
 
2.6 
   
72 33014 sagayam 25 PRIMI 22.5 549 1.10.14 ALIVE 10.4.15 
     
0 7 ZLN 110 115 125 
 
NVD 
 
2.95 
   
73 33206 thamarai 27 
G2 
P1L1 
28.9 646 13.10.14 ALIVE 17.4.15 
     
0 10 TLE 82 
   
NVD 
 
3.00 
   
74 24 sangeetha 25 PRIMI 24.2 742 17.10.14 ALIVE 18.4.15 
     
0 9.5 TLE 95 86 97 
 
LSCS 
 
2.5 
   
75 96 
lakshmimu
rugan 
29 
G2 
P1L1 
26.9 679 19.10.14 ALIVE 22.4.15 
     
0 9.5 ZLN 90 95 98 
 
NVD 
 
3.1 
   
76 102 
pushpa 
bai 
22 PRIMI 21.3 704 12.10.14 ALIVE 25.4.15 
     
0 7 TLE 96 127 125 
 
NVD 
 
2.890 
   
77 157 anjana 27 G2P1L1 23.7 437 2.10.10 ALIVE 29.4.15 
  
YES 
  
1 8.5 TLE 83 80 90 
 
NVD 
 
2.75 
   
78 190 
padmavat
hy 
27 PRIMI 22.4 675 16.10.14 ALIVE 30.4.15 
     
0 7 TLE 96 114 120 
 
NVD 
 
2.600 
   
79 228 jocelyn 24 PRIMI 23.5 492 21.10.14 ALIVE 30.4.15 
     
0 9 TLE 104 95 107 
 
NVD 
 
2.800 
   
80 270 kumari 28 PRIMI 27.5 437 28.10.14 ALIVE 7.5.15 
     
0 10 TLE 75 86 74 
 
NVD 
 
2.95 
   
81 339 stellamary 32 
G3 
P1L1A1 
24.7 694 30.10.14 
STILL 
BIRTH 
11.5.15 yes 
 
YES 
 
ye
s 
1 9.5 TLE 150 
  
insulin Lscs 
 
3.5 
  
85 
82 407 
muthamm
al 
30 PRIMI 22.3 784 2.11.14 ALIVE 11.5.15 
     
0 7 ZLN 85 90 94 
 
NVD 
 
2.600 
   
83 493 lourdu 23 PRIMI 20.1 627 14.10.14 ALIVE 13.5.15 
     
0 6 TLE 92 90 105 
 
LSCS 
 
3.9 
   
84 512 sylvia 26 G2A1 23.9 595 18.10.14 ALIVE 16.5.15 
     
0 8.4 TLE 104 120 110 
 
LSCS 
 
3.6 
   
85 599 gomathy 22 PRIMI 22.6 613 12.10.14 ALIVE 18.5.15 
     
0 7 TLE 104 90 86 
 
NVD 
 
2.75 
   
86 770 bharathi 25 PRIMI 26.3 800 29.9.14 ALIVE 21.5.15 
     
0 8.5 TLE 88 82 80 
 
LSCS 
 
2.600 
   
87 938 anitha 23 PRIMI 23.8 720 13.10.14 ALIVE 25.5.15 
  
YES 
  
1 11 TLE 83 84 90 
 
NVD 
 
2.4 
   
88 1025 prema 25 G2A1 21.3 802 9.10.14 ALIVE 25.5.15 
     
0 8.5 TLE 94 101 98 
 
NVD YES 1.5 
   
89 1172 selvamani 23 PRIMI 22.6 604 19.10.14 ALIVE 28.5.15 
     
0 9 TLE 74 76 96 
 
NVD 
 
2.850 
   
90 1208 umasri 27 
G2 
P1L1 
23.2 674 22.10.14 ALIVE 30.5.15 
     
0 10.5 ZLN 80 92 110 
 
NVD 
 
2.9 
   
91 1397 
kanchana
mala 
26 G2A1 22.4 591 26.10.14 ALIVE 31.5.15 
     
0 9 TLE 110 98 104 
 
LSCS 
 
3.6 
   
92 1592 
deviprabh
a 
29 
G2 
P1L1 
23.1 404 25.10.14 ALIVE 1.6.15 
     
0 10.5 TLE 102 110 105 
 
LSCS 
 
3.550 
   
93 1702 
uma 
prabhu 
22 PRIMI 25.2 1031 17.10.14 ALIVE 5.6.15 
     
0 11 TLE 94 80 78 
 
NVD 
 
2.800 
   
94 1907 raji 29 G2P1L1 20.6 302 24.10.14 ALIVE 6.6.15 
     
0 7 TLE 105 120 106 
 
NVD 
 
2.95 
   
95 1945 mala 22 PRIMI 22.5 681 28.10.14 ALIVE 12.6.15 
     
0 9.5 TLE 84 78 90 
 
NVD YES 2.100 
   
96 2045 
mary 
daniel 
28 
G2 
P1L1 
27.8 991 2.11.14 
STILLBI
RTH 
15.6.15 
     
0 9 TLE 180 
  
INSULI
N 
LSCS 
 
4.2 
  
95 
97 2432 karthika 25 PRIMI 24.8 745 12,11.14 ALIVE 19.6.15 
     
0 11 ZLN 86 99 87 
 
NVD 
 
2.800 
   
98 2773 malathy 22 PRIMI 26.2 686 23.11.14 ALIVE 22.6.15 
     
0 11.5 TLE 80 86 90 
 
NVD 
 
2.95 
   
99 2918 devi 29 
G2 
P1L1 
25.9 635 21.11.14 ALIVE 25.6.15 
     
0 10.5 TLE 94 105 110 
 
LSCS 
 
3.20 
   
10
0 
3419 aruna 27 
G3 
P1L1A1 
23.7 432 6.11.14 ALIVE 26.6.15 
     
0 9.5 ZLN 102 94 115 
 
LSCS 
 
3.50 
   
 
 
 
  
 
   
   
   
   
   
 
